- Design
- Phase 3, randomised, double-blind, placebo-controlled crossover trial
- Population
- 134 adolescents and adults with hereditary angioedema; 88 with paired treated attacks
- Primary outcome
- Time to onset of symptom relief
- Effect
- Median 1.28 h (95% CI 1.05–1.52) vs more than 12 h with placebo
RAPIDe-3 was a phase 3 double-blind crossover trial at 59 sites in 24 countries. Adolescents and adults with hereditary angioedema each treated two attacks, one with a 20 mg oral capsule of deucrictibant, a bradykinin B2 receptor antagonist, and one with placebo, in random order.
In the 88 participants with paired attacks, median time to onset of symptom relief was 1.28 hours with deucrictibant against more than 12 hours with placebo. No treatment-related adverse event was severe or serious, and none led to stopping.
Current on-demand treatments are injected or infused, which delays use. An oral option could let patients treat at the first sign of an attack. The drug is investigational and the trial was industry-funded. Laryngeal attacks still need emergency care, whatever is available at home.
- Deucrictibant is investigational and not licensed for use.
- Laryngeal swelling remains an emergency for injected or infused treatment and airway support.
- Patients with hereditary angioedema should carry a written attack plan and their on-demand drug.
- Adrenaline, antihistamines and steroids do not treat bradykinin-mediated attacks.
- In India, access to any licensed on-demand therapy is limited; fresh frozen plasma is often what is available.
Why it matters
Most delay in treating an attack is the time it takes to inject or reach hospital, and an oral drug removes that step.
Don't overread it
Faster symptom relief against placebo does not show it works for laryngeal attacks or matches injected drugs.
The statistics, in plain English
Median onset of relief is the time by which half the attacks had started to improve. With placebo, half had not improved by 12 hours, which is why the figure is given as more than 12.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for top clinical updates, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free